Abstract: Methods involving analysis of pretreatment leukocyte expression profiles for prognostic assessment of seizure outcome following a treatment or medical procedure, such as stereotactic laser amygdalohippocampotomy (SLAH). In one aspect, RNA sequencing (RNA-Seq) on whole blood leukocyte samples is taken from a patient with intractable epilepsy prior to SLAH. Differential expression (DE) analysis revealed 24 significantly dysregulated genes (?2.0-fold change, p-value <0.05, and False Discovery Rate, FDR <0.05) useful in prognostic assessment.

Abstract: The present invention relates to diagnostic assays useful in classification of patients for selection of cancer therapy, and relates to a method of using a select family member of the Wnt signaling pathway (WIF1), an important component of the insulin-like growth factor pathway (IGFBP3), and other signaling factors (e.g., NGFR, IBSP, and HISTLH3G and COL1A2) as prognostic markers and potential therapeutic targets for patients with Glioblastoma Multiforme (GBM). In particular, the present invention is a novel GBM Prognostic Index (GPI) that predicts overall survival (OS) in GBM patients treated with the current standard of care.

Abstract: Methods involving analysis of pretreatment leukocyte expression profiles for prognostic assessment of seizure outcome following a treatment or medical procedure, such as stereotactic laser amygdalohippocampotomy (SLAH). In one aspect, RNA sequencing (RNA-Seq) on whole blood leukocyte samples is taken from a patient with intractable epilepsy prior to SLAH. Differential expression (DE) analysis revealed 24 significantly dysregulated genes (?2.0-fold change, p-value<0.05, and False Discovery Rate, FDR<0.05) useful in prognostic assessment.